BidaskClub downgraded shares of BioScrip, Inc. (NASDAQ:BIOS) from a strong-buy rating to a buy rating in a research report released on Tuesday, August 1st.
Other equities analysts have also recently issued research reports about the stock. Barrington Research lifted their target price on shares of BioScrip to $3.50 and gave the stock an outperform rating in a research report on Monday, June 26th. ValuEngine upgraded shares of BioScrip from a sell rating to a hold rating in a research report on Thursday, July 13th. Finally, Zacks Investment Research upgraded shares of BioScrip from a hold rating to a buy rating and set a $3.00 target price on the stock in a research report on Wednesday, July 5th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $3.75.
BioScrip (NASDAQ:BIOS) opened at 3.09 on Tuesday. The firm’s 50-day moving average is $2.88 and its 200 day moving average is $2.09. The firm’s market capitalization is $393.90 million. BioScrip has a 12 month low of $0.98 and a 12 month high of $3.43.
COPYRIGHT VIOLATION WARNING: “BidaskClub Lowers BioScrip, Inc. (BIOS) to Buy” was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/19/bioscrip-inc-bios-rating-lowered-to-buy-at-bidaskclub-updated-updated.html.
In other BioScrip news, Director Coliseum Capital Management, L sold 886,478 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $3.08, for a total value of $2,730,352.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.30% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in BIOS. Wells Fargo & Company MN raised its stake in shares of BioScrip by 1.0% in the second quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock worth $312,000 after buying an additional 1,100 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of BioScrip by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock worth $1,333,000 after buying an additional 2,622 shares during the period. Roanoke Asset Management Corp NY raised its stake in shares of BioScrip by 2.6% in the first quarter. Roanoke Asset Management Corp NY now owns 233,280 shares of the company’s stock worth $397,000 after buying an additional 6,000 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of BioScrip by 9.8% in the second quarter. The Manufacturers Life Insurance Company now owns 99,569 shares of the company’s stock worth $271,000 after buying an additional 8,914 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of BioScrip by 9.2% in the second quarter. Rhumbline Advisers now owns 130,122 shares of the company’s stock worth $353,000 after buying an additional 10,985 shares during the period. 85.62% of the stock is currently owned by institutional investors and hedge funds.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
What are top analysts saying about BioScrip Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioScrip Inc. and related companies.